A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects

GLAXOSMITHKLINE PERU S.A.,0 个研究点目标入组 0 人开始时间: 2007年11月15日最近更新: 2023年9月4日

试验速览

阶段: 未知
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 0（—）

入选标准

•Subjects with a documented diagnosis of DMT2 and HbA1c 7.5% and 9.5% measured by the central laboratory in Visit 1 and Visit 2.
•Subjects without previous exposure to treatment and who have taken 2 weeks of insulin or 4 weeks of any oral antidiabetic agent in the last 12 months, but none during the 3 months prior to the screening or newly diagnosed subjects and who have been treated with diet and exercise a minimum of 8 weeks.
•Subjects between 18 and 70 years of age inclusive at the time of the selective examination.
•Eligible female subjects should not have reproductive potential (for example, surgically sterilized women regardless of age (for example, total hysterectomy or documented bilateral oophorectomy) or post-menopausal women (for example, they have not had a menstrual period at a minimum of 12 consecutive months.) All female subjects must have a negative urine pregnancy test on the day of the random distribution and before.
•Informed Consent: before performing any of the study procedures, you will
•you must obtain a written informed consent; signed and dated by the subject.

排除标准

•Metabolic Disease: Diagnosis of type 1 diabetes mellitus, history of ketoacidosis that required hospitalization, thyroid disorder, TSH <0.4MUI / L or> 5.5mlU / L (> 5.5 MCUI / mL) on the selective examination, IMG of <25 kg / m ^ or> 40 kg / m2, Major weight gain or loss (defined as> 5% of total body weight) in the three (3) months prior to the selective examination.
•Medication for diabetes: The subject has taken insulin for> 2 weeks in the 12 months prior to the selective examination or at some time in the 3 months prior to the selective examination. The subject has taken an oral antidiabetic medication for more than 4 months. weeks in the 12 months prior to the selective examination or at some time in the 3 months prior to the selective examination.
•Cardiovascular Disease: Recent history or presence of clinically significant cardiovascular disease, including: documented myocardial infarction in the 6 months before the selective examination. Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG), whether it has been planned and / or occurred in the 6 months prior to the selective examination. Unstable angina in the 6 months prior to the selective examination. Clinically significant supraventricular arrhythmias requiring medical therapy or a history of sustained or nonsustained ventricular tachycardia. Heart valve disease, symptomatic, or requiring therapy in addition to the prophylaxis of endocarditis. Cardiac congestive insufficiency (CCI Class II to IV, according to the New York Heart Association (NYHA)) that requires pharmacological treatment. Class I according to NYHA can be included according to the information for the local prescription for pioglitazone. Blood pressure (BP)> 150 / 100mmHg. If a subject receives allowed antihypertensive therapy, then he must take a stable dose of therapy for at least 3 months prior to the screening. Based on the local readings the subject has a QTc interval (from Bazett) 450msec in the selective examination and then two additional ECGs taken with, Other abnormalities in the ECG, clinically significant that, in the opinion of the researcher, may affect the interpretation of Efficacy and safety data or that otherwise contraindicate participation in a clinical study with a new chemical entity. Plasma triglycerides 400mg / dL (4.56mmol / L) at selective examination. If a subject receives lipid-lowering therapy allowed, then he must take a stable dose of therapy for at least 3 months before the screening. Sequestrants of Niacin and bile acid are prohibited.
•Hepatic Disease: The subject has a diagnosis of active hepatitis (surface antigen for hepatitis B or hepatitis C antibodies), or clinically significant elevation of the liver enzyme, including: Any of the following enzymes greater than 2 times the upper limit of the reference range value (LSRR) on selective screening, alanine transaminase (ALT), transaminase aspartate (AST), alkaline phosphatase (AP), subject has a total bilimibin level that is> 1.5 times the LSRR on selective screening , with the exception of suspected or confirmed Gilbert´s disease.
•Pancreatic Disease: Secondary Causes of Diabetes: History of Acute or Chronic Pancreatitis
•Kidney Disease: Significant renal disease in the selective examination,
•Concurrent Illness: The patient has any concurrent condition or clinically significant abnormality identified on the physica

研究者

发起方

GLAXOSMITHKLINE PERU S.A.,

相似试验

进行中（未招募）

不适用

A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve SubjectsMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusType 2 Diabetes Mellitus

EUCTR2007-001463-29-LTGlaxoSmithKline R&D Ltd252

进行中（未招募）

不适用

A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve SubjectsType 2 Diabetes Mellitus

EUCTR2007-001463-29-HUGlaxoSmithKline R&D Ltd252

进行中（未招募）

不适用

EUCTR2007-001463-29-GRGlaxoSmithKline R&D Ltd252

进行中（未招募）

不适用

EUCTR2007-001463-29-CZGlaxoSmithKline R&D Ltd252

进行中（未招募）

不适用

EUCTR2007-001463-29-DEGlaxoSmithKline R&D Ltd252